The three-signal hypothesis of lymphocyte activation/targets for immunosuppression

Dialysis and Transplantation

Volumn 40, Issue 1, 2011, Pages 14-16

  Goral, Simin ^a  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; BELATACEPT; CALCINEURIN INHIBITOR; CD3 ANTIGEN; CYCLOSPORIN A; RAPAMYCIN; T LYMPHOCYTE RECEPTOR;

ARTICLE; CD3+ T LYMPHOCYTE; CYTOKINE PRODUCTION; HUMAN; IMMUNE RESPONSE; IMMUNOREGULATION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FAILURE; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LYMPHOCYTE ACTIVATION; LYMPHOCYTE DIFFERENTIATION; PRIORITY JOURNAL; RENAL REPLACEMENT THERAPY; SIGNAL TRANSDUCTION; TARGET CELL;

EID: 78651404270     PISSN: 00902934     EISSN: 19326920     Source Type: Journal    
DOI: 10.1002/dat.20527     Document Type: Article

References (14)

1. Reicher B, Barda-Saad M,., Multiple pathways leading from the T-cell antigen receptor to the actin cytoskeleton network [published online ahead of print September 6, 2010]. FEBS Lett. DOI: 10.1016/j.febslet.2010.09.002.
2. Nakayama T, Yamashita M,., The TCR-mediated signaling pathways that control the direction of helper T cell differentiation. Semin Immunol. 2010; 22 5 303-309.
3. Shahinian A, Pfeffer K, Lee KP, et al. Differential T cell costimulatory requirements in CD28-deficient mice. Science. 1993; 261 5121 609-612.
4. Sharpe AH, Abbas AK,., T-cell costimulation&m dash;biology, therapeutic potential, and challenges. N Engl J Med. 2006; 355 10 973-975.
5. Dong C, Juedes AE, Temann UA, et al. ICOS co-stimulatory receptor is essential for T-cell activation and function. Nature. 2001; 409 6816 97-101.
6. Vincenti F, Larsen C, Durrbach A, et al. Costimulation blockade with belatacept in renal transplantation. N Engl J Med. 2005; 353 8 770-781.
7. Vincenti F, Charpentier B, Vanrenterghem Y, et al. A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study). Am J Transplant. 2010; 10 3 535-546.
8. Durrbach A, Pestana JM, Pearson T, et al. A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study). Am J Transplant. 2010; 10 3 547-557.
9. Curtsinger JM, Mescher MF,., Inflammatory cytokines as a third signal for T cell activation. Curr Opin Immunol. 2010; 22 3 333-340.
10. Mescher MF, Curtsinger JM, Agarwal P, et al. Signals required for programming effector and memory development by CD8+ T cells. Immunol Rev. 2006; 211: 81-92.
11. Curtsinger JM, Schmidt CS, Mondino A, et al. Inflammatory cytokines provide a third signal for zctivation of naive CD4+ and CD8+ T cells. J Immunol. 1999; 162: 3256-3262.
12. Filatenkov AA, Jacovetty EL, Fischer UB, Curtsinger JM,., CD4 T cell-dependent conditioning of dendritic cells to produce IL-12 results in CD8-mediated graft rejection and avoidance of tolerance. J Immunol. 2005; 174 11 6909-6917.
13. Agarwal P, Raghavan A, Nandiwada SL, et al. Gene regulation and chromatin remodeling by IL-12 and type I IFN in programming for CD8 T cell effector function and memory. J Immunol. 2009; 183 3 1695-1704.
14. Ben-Sasson SZ, Hu-Li J, Quiel J, Cauchetaux S,., IL-1 acts directly on CD4 T cells to enhance their antigen-driven expansion and differentiation. Proc Natl Acad Sci USA. 2009; 106 17 7119-7124.